Moxonidine

*Moxonidinum*

For medical students2 min readUpdated 2026-10-10

Moxonidine (trade names Physiotens, Cint) is a modern central-acting antihypertensive agent classified as an imidazoline derivative. Due to its high selectivity for specific receptors, it provides reliable blood pressure reduction during systematic therapy while differing from its predecessors by significantly better tolerability.

Chemical groupImidazoline derivative

Main targetHigh selectivity for imidazoline I1-receptors

DurationTherapeutic effect persists for more than 12 hours

Elimination60% of the dose is excreted unchanged by the kidneys

Mechanism of Action and Pharmacodynamics

Chemically, moxonidine is an imidazoline derivative. Its pharmacodynamic profile relies on high selectivity for specific I1-imidazoline receptors located in the central nervous system.

At the same time, the drug exhibits extremely low affinity for central α2-adrenergic receptors. This receptor selectivity fundamentally distinguishes it from previous-generation drugs and ensures high efficacy in the systematic treatment of arterial hypertension.

The total duration of the drug's therapeutic effect after administration exceeds 12 hours.

Pharmacokinetics

The pharmacokinetic profile of the drug has several important features that must be considered when prescribing therapy:

Absorption and bioavailability: After oral administration, the drug demonstrates rapid absorption from the intestine. Bioavailability reaches high values at 88%.
Blood concentration: The peak plasma concentration of the active substance is recorded within 1 hour after administration.
Time lag: A key pharmacodynamic feature is that the pronounced decrease in blood pressure lags behind the concentration peak. The maximum hypotensive effect occurs only after 2–4 hours.

Metabolism, Elimination, and Dosing Regimen

During biotransformation in the body, two metabolites are formed. Notably, both are active, but their pharmacological activity is considered low, so they do not significantly contribute to the overall hypotensive effect.

The main elimination pathway is renal. About 60% of the administered dose is excreted by the kidneys in its original, unchanged form.

For the systematic treatment of arterial hypertension, the standard daily dose is 0.4 mg. Considering the pharmacokinetics of the drug, this dose is traditionally divided into 2 doses throughout the day.

Safety Profile and Tolerability

The safety profile of moxonidine compares favorably with its group predecessors (such as clonidine or guanfacine). The main reason for better tolerability lies in the mechanism of action: stimulation of central α2-adrenergic receptors is responsible for the classic side effects of central-acting antihypertensives. Since moxonidine's affinity for them is minimal, adverse reactions occur less frequently.

Mildly expressed effects: Sedation, dry mouth, edema, and the risk of withdrawal syndrome are significantly less pronounced than with first-generation drugs.
Possible reactions: General weakness, rapid fatigue, and dry mouth may be observed in clinical practice. Angioedema and withdrawal syndrome are recorded in rare cases.

Mnemonic

The "1-2-4" rule for pharmacokinetics: at 1 hour — peak in plasma, at 2–4 hours — pronounced drop in blood pressure.

Frequently asked questions

What are the absolute contraindications to prescribing moxonidine?

Absolute contraindications to moxonidine include severe cardiac conduction disturbances and heart failure. These include:

Sick sinus syndrome — including SSS;
Sinoatrial block — grade 2–3;
Atrioventricular block — grade 2–3;
Pronounced bradycardia — with a heart rate of less than 50 beats per minute;
Heart failure — acute and chronic forms.

In which comorbid conditions is moxonidine the drug of choice due to its effect on carbohydrate metabolism?

Moxonidine is used in patients with hypertension and metabolic disorders, particularly in:

Overweight — against the background of mild arterial hypertension;
Insulin resistance — the drug increases tissue sensitivity to insulin;
Carbohydrate metabolism disorders — therapy improves metabolic parameters.

What is the "time lag" phenomenon when taking moxonidine?

This phenomenon describes the mismatch between the drug's pharmacokinetics and pharmacodynamics. The peak plasma concentration of the substance is reached very rapidly — in 1 hour, but the pronounced clinical effect (blood pressure reduction) is delayed in time and occurs only after 2–4 hours.

Why is moxonidine better tolerated than clonidine and guanfacine?

Due to its high selectivity for I1-imidazoline receptors and low affinity for α2-adrenergic receptors. Stimulation of the latter causes major side effects such as marked sedation and dry mouth.

What is the role of metabolites in the drug's hypotensive action?

Biotransformation produces two active metabolites, but their intrinsic pharmacological activity is extremely low. The main effect is exerted by the parent drug, 60% of which is excreted unchanged by the kidneys.

Go deeper

Comparative characteristics of imidazoline derivatives and first-generation drugs (clonidine, guanfacine).
The role of central α2-adrenergic receptors in the development of side effects of antihypertensive agents.
Mechanisms of development and clinical presentation of withdrawal syndrome in the treatment of arterial hypertension.
Features of renal excretion of unchanged drug forms.
Clinical significance of high oral bioavailability (88%) of medications.